Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model

23Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Oligopeptidic drugs such as β-lactams and angiotensin-converting enzyme inhibitors share the same carders in humans and animals, which results in possible pharmacokinetic interactions. To model such interactions, the effects of quinapril on cephalexin pharmacokinetics were investigated in rats. Blood cephalexin concentrations were measured by liquid chromatography, and the data were analyzed by a noncompartmental method and by fitting a bicompartmental model by a nonlinear mixed-effect modeling approach. Five groups of eight rats were examined. In the first three groups, cephalexin elimination kinetics after intra-arterial administration alone or in combination with quinapril given by the parenteral or the oral route were studied, and the occurrence of a pharmacokinetic interaction was not revealed. The absence of an effect of quinapril on cephalexin elimination after parenteral administration might be explained either by the higher affinity of cephalexin for the renal anionic transport system than that of quinapril or by the much higher concentrations of cephalexin than those of quinapril. In the last two groups, cephalexin was administered by the oral route alone or in combination with quinapril. The mean area under the concentration-time curve (AUC) for cephalexin was increased by ca. 30% by coadministration of quinapril (40.1 versus 31.4 mg- h/liter; P = 0.04). The mean elimination clearance of cephalexin was significantly decreased by quinapril, from 0.81 to 0.64 liter/h/kg of body weight (P < 0.05), probably by competitive inhibition of cephalexin secretion at the tubular level. The mean absorption rate constant of cephalexin was significantly lowered by quinapril (from 0.249 to 0.177 h-1; P < 0.01), without modification of the extent of absorption (89%). This pharmacokinetic interaction could be explained by competitive inhibition of cephalexin active transport by quinapril at the intestinal level.

References Powered by Scopus

Population pharmacokinetics/dynamics

262Citations
N/AReaders
Get full text

Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2

216Citations
N/AReaders
Get full text

Passive and carrier‐mediated intestinal absorption components of captopril

142Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Excretion and ecotoxicity of pharmaceutical and personal care products in the environment

440Citations
N/AReaders
Get full text

Molecularly imprinted solid phase extraction for rapid screening of cephalexin in human plasma and serum

89Citations
N/AReaders
Get full text

Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS

38Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Padoin, C., Tod, M., Perret, G., & Petitjean, O. (1998). Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model. Antimicrobial Agents and Chemotherapy, 42(6), 1463–1469. https://doi.org/10.1128/aac.42.6.1463

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

50%

Researcher 4

40%

Professor / Associate Prof. 1

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

55%

Agricultural and Biological Sciences 2

18%

Engineering 2

18%

Mathematics 1

9%

Save time finding and organizing research with Mendeley

Sign up for free